Esperion Therapeutics (NASDAQ:ESPR) had its price target raised by Deutsche Bank to $100.00 in a research report released on Friday. They currently have a buy rating on the biopharmaceutical company’s stock.
A number of other research analysts also recently commented on the stock. BidaskClub raised shares of Esperion Therapeutics from a buy rating to a strong-buy rating in a report on Saturday, January 13th. UBS Group set a $88.00 price target on shares of Esperion Therapeutics and gave the company a buy rating in a report on Wednesday, January 17th. Credit Suisse Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday, January 17th. They issued an outperform rating and a $103.00 price target for the company. Chardan Capital increased their price target on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the company a neutral rating in a report on Wednesday, December 6th. Finally, Needham & Company LLC raised shares of Esperion Therapeutics from a buy rating to a strong-buy rating and increased their price target for the company from $72.00 to $81.00 in a report on Thursday, December 14th. Seven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $87.36.
Shares of Esperion Therapeutics (NASDAQ ESPR) opened at $80.05 on Friday. The firm has a market cap of $2,120.00, a price-to-earnings ratio of -11.40 and a beta of 2.45. Esperion Therapeutics has a 12 month low of $20.39 and a 12 month high of $82.68.
In related news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $71.79, for a total value of $838,076.46. Following the sale, the director now directly owns 3,177 shares of the company’s stock, valued at approximately $228,076.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 32.50% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Esperion Therapeutics during the fourth quarter worth approximately $222,000. BB&T Securities LLC purchased a new position in shares of Esperion Therapeutics during the fourth quarter worth approximately $263,000. First Mercantile Trust Co. increased its position in shares of Esperion Therapeutics by 56.0% during the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock worth $279,000 after acquiring an additional 1,519 shares during the period. Creative Planning purchased a new position in shares of Esperion Therapeutics during the fourth quarter worth approximately $314,000. Finally, Oakmont Partners LLC purchased a new position in shares of Esperion Therapeutics during the fourth quarter worth approximately $323,000. 91.69% of the stock is currently owned by institutional investors.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.